Novo Nordisk A/S Common Stock (NY:NVO)

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

September 20, 2025

Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs ↗

September 20, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

Topics Economy

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Topics Artificial Intelligence Economy Intellectual Property

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

Topics Artificial Intelligence Economy Intellectual Property

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds ↗

September 19, 2025

Via Benzinga

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

September 19, 2025

From Faruqi & Faruqi LLP

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

September 19, 2025

From Bragar Eagel & Squire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO

September 19, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO

September 19, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors. ↗

September 19, 2025

Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting.

Via Investor's Business Daily

Why Shares in Novo Nordisk Soared This Week ↗

September 19, 2025

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.

A Wegovy pill may be the right medicine to get Novo Nordisk stock moving again.

Why Novo Nordisk Stock Popped Again Today ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Via Benzinga

Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today ↗

September 18, 2025

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

Topics Government

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal ↗

September 18, 2025

Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's...

Via Benzinga

Topics Artificial Intelligence

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

September 18, 2025

From Bernstein Liebhard LLP

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

September 18, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

September 18, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy ↗

September 18, 2025

Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.

Via Investor's Business Daily

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study ↗

September 18, 2025

Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

September 18, 2025

Competition in various directions is affecting the company's fastest-growing product.